Doxycycline

Generic Name: Doxycycline

Brand Names: Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄N_₂O_₈

CAS Number: 564-25-0

Unique Ingredient Identifier: 334895S862

Background: Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.

Indication: Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:

It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions: Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection

Clinical Trials

Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial

Phase 2

Completed

Conditions: Chronic Rhinosinusitis
Nasal Polyps

Interventions: Drug: placebo
Drug: doxycycline 100 mg

First Posted Date: 2010-09-10

Last Posted Date: 2018-06-15

Lead Sponsor: University Hospital, Ghent

Target Recruit Count: 33

Registration Number: NCT01198912

Locations: 🇩🇪
Univ.-HNO-Klinik, St. Elisabeth Hospital, Bochum, Germany
🇧🇪
University Hospital Ghent, Ghent, Belgium

Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)

Not Applicable

Completed

Conditions: Rheumatoid Arthritis
Periodontal Disease
Psoriatic Arthritis

Interventions: Drug: doxycycline
Drug: vancomycin

First Posted Date: 2010-09-10

Last Posted Date: 2015-01-13

Lead Sponsor: NYU Langone Health

Target Recruit Count: 178

Registration Number: NCT01198509

Locations: 🇺🇸
NYU Hospital for Joint Diseases, New York, New York, United States
🇺🇸
Bellevue Hospital, New York, New York, United States

Doxycycline Versus Standard Care to Prevent Seroma Formation

Not Applicable

Withdrawn

Conditions: Seroma

Interventions: Drug: doxycycline
Other: No intervention

First Posted Date: 2010-08-26

Last Posted Date: 2015-04-14

Lead Sponsor: Northwell Health

Registration Number: NCT01188954

Locations: 🇺🇸
Staten Island University Hospital, Staten Island, New York, United States

Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis

Phase 2

Completed

Conditions: Transthyretin Amyloidosis

Interventions: Drug: Doxycycline + Tauroursodeoxycholic acid

First Posted Date: 2010-07-29

Last Posted Date: 2016-02-25

Lead Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

Target Recruit Count: 40

Registration Number: NCT01171859

Locations: 🇮🇹
Amyloid Research and Treatment Centre, Biotechnology Research Laboratories, Pavia, Italy

Antibiotic Treatment of Multiple Erythema Migrans

Not Applicable

Conditions: Multiple Erythema Migrans

Interventions: Drug: ceftriaxone
Other: erythema migrans patients treated with doxycycline
Drug: doxycycline

First Posted Date: 2010-07-16

Last Posted Date: 2017-05-05

Lead Sponsor: University Medical Centre Ljubljana

Target Recruit Count: 500

Registration Number: NCT01163994

Locations: 🇸🇮
UMC Ljubljana, Department of Infectious Diseases, Ljubljana, Slovenia

The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

Phase 2

Completed

Conditions: Pelvic Inflammatory Disease

Interventions: Drug: Ceftriaxone
Drug: Doxycycline
Drug: Placebo Oral Capsule
Drug: Metronidazole

First Posted Date: 2010-07-12

Last Posted Date: 2018-07-10

Lead Sponsor: Harold Wiesenfeld

Target Recruit Count: 233

Registration Number: NCT01160640

Locations: 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Allegheny County Health Department Sexually Transmitted Diseases Clinic, Pittsburgh, Pennsylvania, United States
🇺🇸
UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States

Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

Phase 3

Completed

Conditions: Urogential Chlamydia Trachomatis Infection

Interventions: Drug: Doxycyline Hyclate tablet
Drug: Vibramycin (doxycyline hyclate) capsule

First Posted Date: 2010-04-30

Last Posted Date: 2012-01-27

Lead Sponsor: Warner Chilcott

Target Recruit Count: 495

Registration Number: NCT01113931

Locations: 🇺🇸
Research Site, Tacoma, Washington, United States

Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients

Not Applicable

Completed

Conditions: Cystic Fibrosis

Interventions: Other: placebo
Drug: Doxycycline

First Posted Date: 2010-04-28

Last Posted Date: 2017-03-06

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 40

Registration Number: NCT01112059

Locations: 🇺🇸
University of alabama at Birmingham, Birmingham, Alabama, United States

Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate

Phase 2

Conditions: Mucositis

Interventions: Drug: Doxycycline hyclate

First Posted Date: 2010-03-16

Last Posted Date: 2010-03-16

Lead Sponsor: Metropolitan Autonomous University

Target Recruit Count: 164

Registration Number: NCT01087476

Locations: 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Mexico

Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy

Phase 4

Terminated

Conditions: Periodontitis

Interventions: Drug: Placebo
Drug: Doxycycline
Procedure: modified/simplified papilla preservation flap; scaling
Biological: Prefgel/Emdogain
Drug: 0.12% chlorhexidine gluconate solution
Drug: Ibuprofen 400 mg (if necessary)
Drug: 1% chlorhexidine gluconate gel (if necessary)

First Posted Date: 2009-12-11

Last Posted Date: 2016-11-03

Lead Sponsor: Peter Eickholz

Target Recruit Count: 61

Registration Number: NCT01030666

Locations: 🇩🇪
Dept. of Periodontology, Center of Dental, Oral, and Maxillofacial Medicine, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany
🇩🇪
Section of Periodontology, University Hospital Heidelberg, Heidelberg, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy